Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2011-2021

July 8, 2011
204 Pages - SKU: VSG6488892
Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2011-2021


What are the commercial prospects for the treatment of macular degeneration (AMD) and diabetic retinopathy (DR)? Our new report shows you potential revenues to 2021, discussing commercial opportunities and prospects.

Our report gives you market forecasts to 2021 for those retinal drugs. Discover potential revenues at total world, submarket, product and national levels. Through our research and analysis we aim to save you time and help in your decisions. Find data you need.

See how the drugs Lucentis, Visudyne, Avastin and Macugen can perform to 2021, finding potential revenues. For your needs, we discuss competition in this expanding market.

Our study discusses Roche, Novartis, Pfizer, Sanofi and other companies. There are many opportunities in AMD and DR for large and niche players. Discover prospects for existing competitors and potential market entrants from 2011 to 2021.

There is a strong R&D pipeline for treating retinal disorders. We cover products in development by Regeneron, Bayer, Allergan, OPKO, GSK, Merck, Eli Lilly, Takeda and others. Find R&D trends there.

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Original analysis with revenues, growth rates, market shares, opinion and discussions

In our report you find revenue forecasts, growth rates, market shares, a SWOT/STEP review, an R&D review and opinions from our survey. We provide 153 tables and charts and three research interviews (shown in the accompanying lists).

Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2011-2021 shows you opportunities, challenges and revenue forecasts

Our report gives you the following advantages:
  • Find revenue predictions to 2021 for the world AMD and DR market and its components, seeing revenue growth
  • See revenue forecasts to 2021 for leading products, assessing market potentials and competition
  • Discover revenue forecasts to 2021 for leading national markets - US, Japan, UK, Germany, France, Spain, Italy, China and India
  • Receive supporting data, including epidemiological trends and projections
  • Assess leading companies providing retinal treatments, discovering their activities and outlooks
  • Find out how the retinal drug industry can change and adapt from 2011 to 2021
  • Investigate competition and opportunities influencing the industry and market
  • See what will stimulate and restrain the industry and market from 2011
  • Review R&D for AMD and DR, seeing potential for new products and drug types
  • Investigate commercial requirements, identifying therapeutic needs and opportunities
  • Analyse opportunities and challenges for established and emerging companies
  • View opinions from three interviews with authorities on retinal treatments.
There, you find a distinctive mix of quantitative and qualitative analysis with original predictions. We tackle crucial questions for AMD and DR, helping you to stay ahead.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. This password will be set up for single user and departmental licenses and will be emailed out to the client at the same time as the report. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.

Additional Information

Report Excerpt

4.4.4 Forecast for the Spanish Market, 2011-2021

The fourth-largest AMD and DR pharmaceuticals market in Europe and the sixth-largest globally in 2010, the Spanish market, will face significant cost-containment pressures throughout the forecast period of this report. The country embarked on an overhaul of the health system in 2010, targeting savings of between $3bn and $4bn through these reforms. Central to the reforms were a change to the national reference price system for pharmaceuticals and the creation of a central purchasing agency. Along with mandatory price discounts on reimbursed pharmaceutical products decreed by the 2010 overhaul, these measures are designed to reduce the cost of pharmaceutical products in Spain. Pharmaceuticals are already lower-priced in Spain than in other European countries, and the national health service already pays no more than 60% of the cost of prescriptions, individual patients having to pay for the outstanding costs. Spanish healthcare spending nevertheless reached 9.0% of GDP in 2010, higher than the UK and Japan, among the industrialised Western nations. The Spanish attempts to reduce healthcare expenditure have been some of the most extensive and dramatic seen in Europe since the global economic situation worsened in 2008.

Companies Listed

Abbott Laboratories
Advanced Vision Science
Agency for Nutrition and Food Safety (Spain)
Alcon Laboratories
Alimera Sciences
American Academy of Ophthalmology (AAO)
American Society of Retina Specialists (ASRS)
AmpliPhi Biosciences Corporation
Assogenerici (Italian Association of Generic Medicines Industry)
Astellas Pharma
Aurobindo Pharma
Bausch & Lomb
Bayer Healthcare
BioInvent International
Bristol-Myers Squibb
Cambridge University
Centre for Molecular and Vascular Biology, KU Leuven
CIBA Vision
Claris Lifesciences
Control Delivery Systems
Daiichi Sankyo
Delenex Therapeutics
Diabetic Retinopathy Clinical Research Network (DRCR)
Dr. Reddy's Laboratories
Eli Lilly
Emory University
European Medicines Agency (EMA)
Eyetech Pharmaceuticals
Food and Drug Administration (US FDA)
Fovea Pharmaceuticals
Gene Signal
Harvard Medical School
iCo Therapeutics
Institute of Experimental Medicine (St. Petersburg, Russia)
Intas Biopharmaceuticals
International Diabetes Foundation
Isis Pharmaceuticals
ISTA Pharmaceuticals
Joslin Diabetes Center
KAI Pharmaceuticals
Lupin Pharma
Merck & Co.
National Eye Institute (NEI)
National Health Service (NHS)
National Institute for Clinical Excellence (NICE)
New England Journal of Medicine (NEJM)
Nobilon International
Novo Nordisk
Oklahoma Medical Research Foundation
OM Pharmaceuticals
Onco Therapies
Opko Health
Othera Pharmaceuticals
Oxford BioMedica
Piramal Healthcare
PlaNrt Finance
Potentia Pharmaceuticals
Provincial Institute for the Control of Pharmaceutical and Biologic Products (China)
Purdue University
Quark Pharmaceuticals
Ranbaxy Laboratories
Reliance Life Sciences
ReVision Therapeutics
Santen Pharmaceutical
Sanwa Kagaku Kenkyusho (a subsidiary of Suzuken)
Shandong University
Shanghai Institute for Biological Sciences
Silence Therapeutics
Sirion Therapeutics
Sirna Therapeutics
State Food and Drug Administration (China)
Strides Arcolab
Symphony ViDA
Takeda Pharmaceutical Company
University College London
University of Florida
University of Kentucky College of Medicine
Vitreoretinal Technologies
World Health Organization (WHO)

More Ophthalmology reports by Visiongain

Ophthalmic Drugs Market Forecast 2014-2024 by Visiongain
Ophthalmic Drugs Market Forecast 2014-2024 Prospects for Leading Companies Ophthalmic drugs – new study showing you trends, R&D progress, and predicted revenues Where ...
Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024 by Visiongain
Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024 New study shows you commercial prospects for leading eye drug producers What does the future hold ...
Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Market 2014-2024 by Visiongain
Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Market 2014-2024 Analysis of revenues and R&D prospects for those eye drugs - you explore ...
Ophthalmic Drugs: World Market Prospects 2013-2023 by Visiongain
Ophthalmic Drugs: World Market Prospects 2013-2023 How to find trends and revenue predictions for the ophthalmic drug industry What are the commercial prospects for ...
See all reports like this >>



    Electronic Access
Single User Fulfilled By Publisher
  USD 2,503  
    Electronic Access
Departmental 1-5 Users
  USD 4,858  
    Electronic Access
Global Site License Fulfilled By Publisher
  USD 11,338  
US: 800.298.5699
Int'l: +1.240.747.3093

Share this report

    Other tasks

    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!